Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 0.3% – Here’s Why

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) rose 0.3% during mid-day trading on Wednesday . The company traded as high as $6.72 and last traded at $6.49. Approximately 6,993,546 shares were traded during trading, a decline of 73% from the average daily volume of 25,691,047 shares. The stock had previously closed at $6.47.

Analysts Set New Price Targets

Several brokerages have recently commented on RXRX. KeyCorp decreased their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a report on Wednesday, January 8th. Cowen reiterated a “hold” rating on shares of Recursion Pharmaceuticals in a research note on Friday. Leerink Partners cut their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a report on Friday, February 28th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, February 6th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, Recursion Pharmaceuticals presently has an average rating of “Hold” and an average price target of $8.25.

Recursion Pharmaceuticals Stock Up 1.5 %

The firm has a market capitalization of $2.57 billion, a price-to-earnings ratio of -4.28 and a beta of 0.86. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The business has a fifty day moving average price of $7.69 and a two-hundred day moving average price of $7.09.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business had revenue of $4.60 million during the quarter, compared to analyst estimates of $19.04 million. During the same quarter last year, the company posted ($0.42) EPS. Recursion Pharmaceuticals’s quarterly revenue was down 57.8% compared to the same quarter last year. On average, equities analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Institutional Trading of Recursion Pharmaceuticals

A number of hedge funds have recently modified their holdings of the stock. Allspring Global Investments Holdings LLC acquired a new position in Recursion Pharmaceuticals in the third quarter valued at approximately $25,000. Decker Retirement Planning Inc. acquired a new position in shares of Recursion Pharmaceuticals in the 4th quarter valued at $26,000. Private Trust Co. NA purchased a new stake in Recursion Pharmaceuticals during the fourth quarter worth $27,000. GAMMA Investing LLC grew its position in Recursion Pharmaceuticals by 1,979.2% during the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock valued at $35,000 after buying an additional 4,948 shares during the period. Finally, Farther Finance Advisors LLC increased its holdings in Recursion Pharmaceuticals by 176.9% in the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock valued at $42,000 after buying an additional 4,091 shares in the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.